ClinicalTrials.gg
TerminatedNCT00486720Updated Jul 3, 2015Results posted

Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)

A Phase 2 interventional study of vorinostat and vorinostat in Myelodysplastic Syndromes, Blood Disease and Bone Marrow Disease, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-03.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing vorinostat in Myelodysplastic Syndromes — none open to participants now, 3 under way, none of them phase 3. Vorinostat · Myelodysplastic Syndromes.

Enrollment
7th of 11
22 · median 43
Started
2007
with 1 other
Phase 2
5 of 11
none open now
Registered
3rd of 11
by date
Lead sponsor
2 of 11
Merck Sharp & Dohme LLC

Among the 11 studies testing vorinostat in Myelodysplastic Syndromes, this one is the 7th largest by enrollment, is one of 2 that started in 2007, is one of 5 in phase 2, and was the 3rd registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

None of the 11 studies testing vorinostat in Myelodysplastic Syndromes is open now. The open studies under Myelodysplastic Syndromes, anywhere →

Where they have run

About vorinostat

Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing vorinostat in Myelodysplastic Syndromes as a file.
02

Study summary

This study is to evaluate the efficacy, safety and tolerability of vorinostat in patients with lower risk Myelodysplastic Syndrome (MDS).

03

Conditions studied

  • Myelodysplastic Syndromes
  • Blood Disease
  • Bone Marrow Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient is a male or female, at least 18 years of age with low or intermediate-1 risk Myelodysplastic Syndrome (MDS) defined by the International Prognostic Scoring System

  • Patient has previously untreated disease, or has received up to one prior treatment regimen for lower-risk Myelodysplastic Syndrome
  • Patient has a performance status of equal to or less than 2 on the Performance Scale
  • Patient must have adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Patient has clinical evidence of Central Nervous System (CNS) leukemia
  • Patient is pregnant or breastfeeding, or expecting to conceive within the projected duration of the study
  • Patient had prior treatment with a histone deacetylase inhibitor
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    1

    vorinostat 400 mg

    Drug: vorinostat

  • Experimental
    2

    vorinostat 200 mg

    Drug: vorinostat

Interventions

  • vorinostat 400 mg by mouth (P.O.) capsules once daily (q.d.). Treatment in 21 day cycles for up to 8 cycles.

    Also known as: suberoylanilide hydroxamic acid (SAHA), ZOLINZA®

  • vorinostat 200 mg by mouth (P.O.) capsules three times daily (t.i.d.). Treatment in 21 day cycles for up to 8 cycles.

    Also known as: suberoylanilide hydroxamic acid (SAHA), ZOLINZA®

06

What researchers measure

Primary outcomes

  1. Number of Responders and Number of Non-responders Defined by International Working Group Response Criteria

    Number of responders is defined as the number of patients in the analysis population who have complete response (CR), partial response (PR), or hematologic improvement (HI) per International Working Group Response Criteria during the course of the study. Confirmation of CR or PR will require a second assessment performed 4 weeks or more after the initial assessment. Confirmation of HI will require a second assessment performed 8 weeks or more after the initial assessment. Number of non-responders is defined as the number of patients who did not achieve CR, PR or HI in the study.

    Time frame: 2 Years

  2. Safety and Tolerability as Assessed by the Number of Participants With Adverse Events.

    Time frame: Every 21 days while on therapy and at 30 days after the last dose of study therapy

07

Results

Posted Jun 22, 2010
Limitations and caveats
This trial was terminated because the pre-specified futility criterion was met.

Participant flow

Date of first patient in was 26-Jun-2007. The date of last patient last visit for the study was 16-Jul-2009.

Participant flow — Overall Study
MilestoneVorinostat Once Daily Dose ScheduleVorinostat Thrice Daily Dose Schedule
Started1012
Completed00
Not completed1012
Withdrew: Adverse event12
Withdrew: Lack of efficacy46
Withdrew: Physician decision12
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject31
Withdrew: Progressive disease01

Outcome measures

PrimaryNumber of Responders and Number of Non-responders Defined by International Working Group Response Criteria

Number of responders is defined as the number of patients in the analysis population who have complete response (CR), partial response (PR), or hematologic improvement (HI) per International Working Group Response Criteria during the course of the study. Confirmation of CR or PR will require a second assessment performed 4 weeks or more after the initial assessment. Confirmation of HI will require a second assessment performed 8 weeks or more after the initial assessment. Number of non-responders is defined as the number of patients who did not achieve CR, PR or HI in the study.

Time frame:
2 Years
Reported as:
Number · Participants
Number of Responders and Number of Non-responders Defined by International Working Group Response Criteria
ParticipantsVorinostat Once Daily Dose ScheduleVorinostat Thrice Daily Dose Schedule
Responder00
Non-responder912
PrimarySafety and Tolerability as Assessed by the Number of Participants With Adverse Events.
Time frame:
Every 21 days while on therapy and at 30 days after the last dose of study therapy
Reported as:
Number · Participants
Safety and Tolerability as Assessed by the Number of Participants With Adverse Events.
ParticipantsVorinostat Once Daily Dose ScheduleVorinostat Thrice Daily Dose Schedule
With one or more adverse events912
With no adverse events00
With drug-related adverse events411
With serious adverse events25
With serious drug-related adverse events02

Adverse events

Collected over Serious and non-serious adverse experiences occurring from the time of consent up through 30 days after the last dose of study drug were reported.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vorinostat Once Daily Dose Schedule—2/9 (22.2%)9/9 (100%)
Vorinostat Thrice Daily Dose Schedule—5/12 (41.7%)12/12 (100%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventVorinostat Once Daily Dose ScheduleVorinostat Thrice Daily Dose Schedule
Disease progressionGeneral disorders1/90/12
Lung infectionInfections and infestations1/90/12
PneumoniaInfections and infestations1/90/12
Urinary tract infectionInfections and infestations1/90/12
Confusional statePsychiatric disorders1/90/12
Urinary retentionRenal and urinary disorders1/90/12
AnaemiaBlood and lymphatic system disorders0/91/12
NeutropeniaBlood and lymphatic system disorders0/91/12
Splenic haemorrhageBlood and lymphatic system disorders0/91/12
Pericardial effusionCardiac disorders0/91/12
Most frequent other events
Showing 10 of 87
Most frequent other events
EventVorinostat Once Daily Dose ScheduleVorinostat Thrice Daily Dose Schedule
DiarrhoeaGastrointestinal disorders5/911/12
NauseaGastrointestinal disorders5/99/12
AnaemiaBlood and lymphatic system disorders1/97/12
FatigueGeneral disorders4/97/12
VomitingGastrointestinal disorders4/95/12
AnorexiaMetabolism and nutrition disorders1/95/12
NeutropeniaBlood and lymphatic system disorders2/94/12
HypokalaemiaMetabolism and nutrition disorders0/94/12
Muscle spasmsMusculoskeletal and connective tissue disorders3/90/12
DizzinessNervous system disorders2/93/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)Vorinostat Once Daily Dose ScheduleVorinostat Thrice Daily Dose ScheduleTotal
Mean69.0 ± 18.564.0 ± 10.566.0 ± 14.1
Sex: Female, Male
Sex: Female, Male(Participants)Vorinostat Once Daily Dose ScheduleVorinostat Thrice Daily Dose ScheduleTotal
Female156
Male8715
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Vorinostat Once Daily Dose ScheduleVorinostat Thrice Daily Dose ScheduleTotal
White91019
Black011
Asian011
Eastern Cooperative Oncology Group (ECOG) Performance Scale Status
Eastern Cooperative Oncology Group (ECOG) Performance Scale Status(participants)Vorinostat Once Daily Dose ScheduleVorinostat Thrice Daily Dose ScheduleTotal
0 = Normal Activity41014
1 = Symptoms, but ambulatory415
2 = In bed < 50% of the time112
International Prognostic Scoring System Risk (IPSS)
International Prognostic Scoring System Risk (IPSS)(Participants)Vorinostat Once Daily Dose ScheduleVorinostat Thrice Daily Dose ScheduleTotal
Low347
Intermediate-16814
Prior Myelodysplastic Syndromes Therapy
Prior Myelodysplastic Syndromes Therapy(Participants)Vorinostat Once Daily Dose ScheduleVorinostat Thrice Daily Dose ScheduleTotal
Yes639
No3912
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2010, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2007
First posted
Jun 15, 2007
Start
Jun 2007
Primary completionActual
Jul 2009
CompletionActual
Jul 2009
Results first posted
Jun 22, 2010
Last update
Jul 3, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00486720
Responsible party
Sponsor
First posted
Jun 15, 2007
Start date
Jun 2007
Primary completion
Jul 2009
Completion
Jul 2009
Results posted
Jun 22, 2010
Last update
Jul 3, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorinostat

Start the discussion